← Leaderboards
Eric C Westman
Duke University
$1,261,730
Attributed
$1,261,730
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $210.1K · FY2005–14$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$1,261,730 · 2
By mechanism
P50$799,730 · 1
R21$462,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Donald B Katz$16,466,812
- Hubert O Amrein$11,631,450
- Susan S Schiffman$3,086,036
- Cathrine Hoyo$22,947,053
- Hiroaki Matsunami$14,386,892
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchClinical TrialsSmoking CessationHuman SubjectBaseEnrollmentEnsureAdvertisingDesignContractsCatchment AreaCessation Of LifeCessation ResearchEffectivenessComplexCigarette SmokingCigarette SmokerClinical Research SiteClinical TreatmentAdvertisementsClinical Trials NetworkCohort StudiesCommunicationEffective Therapy
Grant awards (8)
Recruitment Core$194,871
P50 · FY2014 · DA · contact PI
Recruitment Core$122,812
P50 · FY2013 · DA · contact PI
Recruitment Core$131,867
P50 · FY2012 · DA · contact PI
Recruitment Core$210,073
P50 · FY2011 · DA · contact PI
Recruitment Core$140,107
P50 · FY2010 · DA · contact PI
Oral Nicotine Replacement for Smoking Cessation$154,000
R21 · FY2005 · DA
Oral Nicotine Replacement for Smoking Cessation$154,000
R21 · FY2004 · DA
Oral Nicotine Replacement for Smoking Cessation$154,000
R21 · FY2003 · DA